Over 300 million women experience chronic pelvic pain of which 190 million have endometriosis. Despite this, diagnosis of many of the common indications that cause women to experience chronic pelvic pain, including endometriosis, takes 8+ years from symptom onset. On average, affected women have twice as many medical consultations before receiving a diagnosis, and a significant number will require emergency room treatment. There’s a massive need for tools that not only enable earlier diagnosis, but also ensure more equitable, personalised, predictive, and preventative women's health.
TRANSCEND is a 2-year project in which PrecisionLife will develop and clinically validate a rapid, non-invasive precision medicine test to evaluate a patient’s risk of endometriosis and other diseases associated with chronic pelvic pain, and identify the mechanisms underpinning their disease. With this test, we aim to improve referral speed and accuracy for women with chronic pelvic pain, reducing waiting lists, unnecessary surgeries, and improving patient outcomes.
TRANSCEND will also enable testing of repurposing drug candidates identified by PrecisionLife in targeted groups of at-risk patients with endometriosis. These drugs have a clear genetic rationale and are supported by the mechanostic test that indicates which patients are most likely to benefit from them. This is the fastest and cheapest way to find medicines that will be effective for patients with endometriosis, whose current pharmaceutical options are limited to hormonal therapies with limited efficacy and significant side effects. This project also includes additional go-to-market activities that will support market targeting, engage clinicians and patient groups, and work with regulatory bodies to support approval and uptake.
